NCT04716231View on ClinicalTrials.gov

Atacicept in Subjects With IgA Nephropathy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

June 29, 2023

Primary Completion Date

May 15, 2025

Study Completion Date

July 31, 2028

Conditions
IgA NephropathyBerger Disease
Interventions
BIOLOGICAL

Atacicept

Once weekly subcutaneous (SC) injections by prefilled syringe

OTHER

Placebo to match Atacicept

Once weekly subcutaneous (SC) injections by prefilled syringe

Trial Locations (1)

94005

ORIGIN 3 Global Site Contact Information, Brisbane

All Listed Sponsors
lead

Vera Therapeutics, Inc.

INDUSTRY